Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ad26.cov2-s - suspension injectable - suspension: ad26.cov2-s 8,92 log10 infekt. einheiten, hydroxypropylbetadexum, acidum citricum monohydricum, 1-(4-tolyl)-ethanolum, acidum hydrochloridum, polysorbatum 80, natrii chloridum, natrii hydroxidum, trinatrii citras dihydricus, aqua ad iniectabile, pro dosi. - covid-19 vaccine janssen ist indiziert für die aktive immunisierung von personen im alter von 18 jahren und älter zur prävention der durch das sars-cov-2 verursachten covid-19-erkrankung - les vaccins

Union européenne - français - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccins - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccins - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccins - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

janssen-cilag international n.v - ad26.cov2.s - suspension injectable - antiinfectieux generaux a usage systemique - vaccins - janssen covid-19 vaccine est indiqué pour l'immunisation active pour la prévention de la maladie covid- 19 chez les adultes âgés de 18 ans et plus. l'utilisation de ce vaccin se fait selon les recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Tunisie - français - Ministère de la Santé, Direction de l'inspection Pharmaceutique

astrazeneca ab suede - vaccin recombinant à base d'adénovirus anti-covid-19 - solution injectable - antiinfectieux generaux a usage systemique - vaccins - indiqué pour la prévention des infections par le coronavirus (covid-19) causées par sars-cov -2 chez les sujets âgés de 18 ans et plus .

Union européenne - français - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaccins - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 et 5. 1 in product information document). l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccins - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.